Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an announcement.
Vicore Pharma Holding AB has published its 2025 annual report, which compiles a broad overview of the company’s operations, scientific progress, sustainability work, intellectual property, and shareholder information. The document also includes full statutory reporting, such as the administration report, multi-year financial overview, audited financial statements, and corporate governance report, with the ESEF version designated as the official record for regulatory and investor use.
The most recent analyst rating on (SE:VICO) stock is a Sell with a SEK9.50 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a publicly listed biopharmaceutical company focused on developing innovative therapies, with operations and reporting aligned to the European Single Electronic Format standards. Its activities, governance, and financial performance are detailed in an annual report aimed at shareholders and other capital market stakeholders.
Average Trading Volume: 672,670
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.06B
For an in-depth examination of VICO stock, go to TipRanks’ Overview page.